RAS-positive thyroid nodules

Area of Science:

• Endocrinology
• Oncology
• Molecular Diagnostics

Background:

• Thyroid nodules with indeterminate cytology pose diagnostic challenges.
• Oncogene testing, including for rat sarcoma viral oncogene homolog (RAS) mutations, is increasingly used for risk stratification.
• RAS mutations have historically been associated with oncogenesis, but their presence in thyroid nodules is complex.

Purpose of the Study:

• To review the uncertainties in managing RAS-positive thyroid nodules.
• To clarify the clinical significance of RAS mutations in thyroid nodules.
• To assess the implications of RAS mutations for thyroid nodule diagnosis and management.

Main Methods:

• Review of current literature on RAS mutations in thyroid nodules.
• Analysis of diagnostic and prognostic implications of RAS testing.
• Evaluation of clinical outcomes for RAS-positive thyroid nodules.

Main Results:

• RAS-positive thyroid nodules frequently present with indeterminate cytology.
• RAS mutations are detected in both benign and malignant thyroid lesions.
• Long-term follow-up of RAS-positive nodules with benign cytology indicates an indolent behavior, not typically leading to malignant transformation.
• Many lesions previously classified as follicular variant of papillary thyroid carcinoma with RAS mutations are now reclassified as noninvasive follicular thyroid neoplasm with papillary-like nuclear features, signifying a less aggressive nature.

Conclusions:

• A RAS-positive diagnosis for a thyroid nodule does not automatically equate to malignancy.
• The clinical and surgical management strategies for RAS-positive thyroid nodules require further refinement.
• RAS testing aids in risk assessment but necessitates careful interpretation in the context of overall nodule characteristics.